Loading
A phase 3 trial of Trastuzumab rezetecan, Capecitabine, Eribulin, Gemcitabine and Paclitaxel / nab-paclitaxel in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial is a phase 3 interventional study registered as NCT05814354 by Jiangsu HengRui Medicine Co., Ltd., with 551 participants enrolled, started 2023-06-30 and due to reach its primary completion in 2026-03-20. Interventions recorded: SHR-A1811 and Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Topoisomerase-I inhibitors (and ADC payloads), Capecitabine, Gemcitabine and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/